| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | FCRL2; FCRH2; IFGP4; IRTA4; SPAP1; SPAP1A; SPAP1B; SPAP1C |
| Entrez GeneID | 79368 |
| clone | 7B12A3 |
| WB Predicted band size | 55.5kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human CD307B (AA: extra 20-253) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是假设存在的关于CD307B抗体的文献示例(非真实文献，仅作格式参考)：
---
1. **文献名称**：*CD307B as a novel regulator of B-cell signaling in autoimmune diseases*
**作者**：Zhang et al., 2020
**摘要**：研究揭示了CD307B(Fc受体家族成员)在B细胞活化中的调控作用，发现其通过抑制BCR信号通路减轻小鼠模型中的类风湿性关节炎症状，提示其作为自身免疫疾病治疗靶点的潜力。
2. **文献名称**：*Structural characterization of CD307B and its interaction with antigens*
**作者**：Smith et al., 2018
**摘要**：通过X射线晶体学解析CD307B胞外域结构，发现其与IgG的结合模式不同于其他Fc受体，并提出其可能参与抗原呈递或免疫复合物清除的新机制。
3. **文献名称**：*CD307B expression correlates with poor prognosis in B-cell lymphoma*
**作者**：Tanaka et al., 2019
**摘要**：临床分析显示，CD307B在弥漫大B细胞淋巴瘤中高表达，且与化疗耐药性相关，提示其可作为预后标志物或单抗药物开发靶点。
4. **文献名称**：*CD307B deficiency enhances anti-tumor immunity in murine models*
**作者**：Wang et al., 2021
**摘要**：CD307B敲除小鼠的肿瘤微环境中T细胞浸润增加，肿瘤生长受抑制，表明靶向CD307B可能通过调节免疫抑制微环境增强癌症免疫治疗效果。
---
注：以上内容为模拟虚构，实际文献需通过PubMed、Google Scholar等平台检索。
CD307B, also known as Fc receptor-like protein 5 (FCRL5), is a member of the Fc receptor-like (FCRL) family, which shares structural homology with classical Fc receptors but lacks binding affinity for immunoglobulins. Expressed predominantly on B cells, particularly memory B cells and plasma cells, CD307B is implicated in regulating B-cell activation, differentiation, and immune responses. Its extracellular region contains immunoglobulin-like domains, while its cytoplasmic tail features immunoreceptor tyrosine-based inhibitory motifs (ITIMs) and immunoreceptor tyrosine-based switch motifs (ITSMs), suggesting dual regulatory roles in signaling pathways.
CD307B has garnered attention for its potential involvement in autoimmune diseases, infections, and B-cell malignancies. Studies highlight its upregulated expression in conditions like rheumatoid arthritis, systemic lupus erythematosus (SLE), and chronic lymphocytic leukemia (CLL), where it may modulate pathogenic antibody production or cell survival. Additionally, CD307B serves as a marker for atypical memory B cells in malaria and HIV, linking it to chronic antigen exposure.
Therapeutic interest in CD307B arises from its restricted expression on abnormal B-cell subsets, making it a candidate for targeted therapies. Antibodies against CD307B are being explored for diagnostic applications, drug delivery, and engineered CAR-T cell therapies. However, its precise ligand interactions and signaling mechanisms remain under investigation, necessitating further research to clarify its role in immune regulation and disease pathogenesis.
×
